Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-05

AUTHORS

I. Vergote, J.F.R. Robertson, U. Kleeberg, G. Burton, C.K. Osborne, L. Mauriac

ABSTRACT

PURPOSE: This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex'). PATIENTS AND METHODS: A combined total of 423 patients received fulvestrant 250 mg as a monthly intramuscular injection. After progression on fulvestrant, some patients received another endocrine therapy. Responses to subsequent endocrine therapy were assessed using a questionnaire sent to the trial investigators. Best responses were classified as a complete or partial response (CR or PR), stable disease (SD) lasting > or = 24 weeks, or disease progression. RESULTS: Follow-up data were available for 54 patients who derived clinical benefit (CB, defined as CR, PR or SD) from fulvestrant and who received subsequent endocrine therapy, resulting in a PR in 4 patients, SD in 21 patients, and disease progression in 29 patients. Data were available for 51 patients who derived no CB from fulvestrant and who received further endocrine therapy, resulting in a PR in 1 patient, SD in 17 patients, and disease progression in 33 patients. Aromatase inhibitors were used as subsequent endocrine therapy in > 80% of patients. CONCLUSIONS: After progression on fulvestrant, patients may retain sensitivity to other endocrine agents. Fulvestrant provides an additional option to existing endocrine therapies for the treatment of advanced or metastatic breast cancer in postmenopausal women, and may provide the opportunity to extend the sequence of endocrine regimens before cytotoxic chemotherapy is required. More... »

PAGES

207-211

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1023983032625

DOI

http://dx.doi.org/10.1023/a:1023983032625

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001709392

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12825855


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Androstenedione", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aromatase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Down-Regulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estradiol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrogen Receptor Modulators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Megestrol Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universitaire Ziekenhuizen Leuven", 
          "id": "https://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "University Hospitals, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vergote", 
        "givenName": "I.", 
        "id": "sg:person.0706143575.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706143575.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Nottingham City Hospital, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "J.F.R.", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Haematologische/Oncologische Praxis, Hamburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kleeberg", 
        "givenName": "U.", 
        "id": "sg:person.01324174537.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324174537.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Louisiana State University Health Sciences Center Shreveport", 
          "id": "https://www.grid.ac/institutes/grid.411417.6", 
          "name": [
            "Louisiana State University Health Science Center, Shreveport, LA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burton", 
        "givenName": "G.", 
        "id": "sg:person.07760047337.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07760047337.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Houston Methodist", 
          "id": "https://www.grid.ac/institutes/grid.63368.38", 
          "name": [
            "Breast Center at Baylor College of Medicine and Methodist Hospital, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osborne", 
        "givenName": "C.K.", 
        "id": "sg:person.01117361752.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117361752.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Bergoni\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.476460.7", 
          "name": [
            "Bergonie Institute, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mauriac", 
        "givenName": "L.", 
        "id": "sg:person.01271107205.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271107205.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00350-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005235495"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0142(19980701)83:1<1::aid-cncr1>3.0.co;2-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011845112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.357", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012787769", 
          "https://doi.org/10.1038/bjc.1996.357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.357", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012787769", 
          "https://doi.org/10.1038/bjc.1996.357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0960-0760(01)00140-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016224520"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1005828731462", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018344209", 
          "https://doi.org/10.1023/a:1005828731462"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000055285", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021121785"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685924", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028594759", 
          "https://doi.org/10.1007/bf00685924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685924", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028594759", 
          "https://doi.org/10.1007/bf00685924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006391902868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037141890", 
          "https://doi.org/10.1023/a:1006391902868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00662401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044518496", 
          "https://doi.org/10.1007/bf00662401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00662401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044518496", 
          "https://doi.org/10.1007/bf00662401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(95)91156-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047740754"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(95)91156-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047740754"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)80309-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054666367"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/87.10.746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059819285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.058", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.22.3758", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074728220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.10.2596", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074814003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074881954", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077661065", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.7.2000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082907367"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.2.453", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083213024"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083239805", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-05", 
    "datePublishedReg": "2003-05-01", 
    "description": "PURPOSE: This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex').\nPATIENTS AND METHODS: A combined total of 423 patients received fulvestrant 250 mg as a monthly intramuscular injection. After progression on fulvestrant, some patients received another endocrine therapy. Responses to subsequent endocrine therapy were assessed using a questionnaire sent to the trial investigators. Best responses were classified as a complete or partial response (CR or PR), stable disease (SD) lasting > or = 24 weeks, or disease progression.\nRESULTS: Follow-up data were available for 54 patients who derived clinical benefit (CB, defined as CR, PR or SD) from fulvestrant and who received subsequent endocrine therapy, resulting in a PR in 4 patients, SD in 21 patients, and disease progression in 29 patients. Data were available for 51 patients who derived no CB from fulvestrant and who received further endocrine therapy, resulting in a PR in 1 patient, SD in 17 patients, and disease progression in 33 patients. Aromatase inhibitors were used as subsequent endocrine therapy in > 80% of patients.\nCONCLUSIONS: After progression on fulvestrant, patients may retain sensitivity to other endocrine agents. Fulvestrant provides an additional option to existing endocrine therapies for the treatment of advanced or metastatic breast cancer in postmenopausal women, and may provide the opportunity to extend the sequence of endocrine regimens before cytotoxic chemotherapy is required.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1023983032625", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "79"
      }
    ], 
    "name": "Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy", 
    "pagination": "207-211", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "082435e4f60ab6666305e03723d31a4ae196dc9d7d5ffa0d4eb63c7130cfb8c7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12825855"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1023983032625"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001709392"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1023983032625", 
      "https://app.dimensions.ai/details/publication/pub.1001709392"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000502.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023%2FA%3A1023983032625"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'


 

This table displays all metadata directly associated to this object as RDF triples.

283 TRIPLES      21 PREDICATES      75 URIs      46 LITERALS      34 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1023983032625 schema:about N06d9f9480df241ffa0c27c0a5c6b84fe
2 N0d104b7458a84503afadc5f6c1559513
3 N1cc4e956d9644512b426ce156a2a2432
4 N26b43798dcd24300b05e1e9d69c1e02a
5 N278f4e9fd1934876a1276fd4aa5e1f0d
6 N2b0bef58d98c4ec1a24e114f39fac16b
7 N453f92c28598417f98e98ba1d51931c7
8 N5aed25bae80f40e7a52b7ca6a589cd18
9 N5dc5591765ce49609288c6bd53d9f90b
10 N68bcfbdaf34e4261b72342252761c8bd
11 N6de0ae024d704e4d95933e56d675c786
12 N7b88e956da20412f879b89a4c4131bc8
13 N85d49a0f0a16402abdf71211e6551d8d
14 Na3a19d10152d4f50a43c5b09f23a8418
15 Nbbaf5e80fc574f789f597f3d287193bd
16 Nc720a8327e7a4360836b6132fcac19b7
17 Nc73a66ce19714d13ac0e865ff936b177
18 Ne77e59d02c7c469595230c686e06b318
19 Nea6bc5aec783481387c3832282ead3ff
20 Nec2c1416cae44162ba593d96adbf5549
21 Nec6133a8a1264cfc9747d131a4dccadf
22 Nf5ef4d9fcac943418d18753eb7238ba9
23 Nfab6b675571a4ee9bd4b4024ea2e7933
24 Nfb27ebde1c2b4886bd39d2d649c84d12
25 Nfecae56841424ed5a9b0783260caacab
26 anzsrc-for:11
27 anzsrc-for:1112
28 schema:author Ne1fd5681b3cb416e8947f2bbaa53c0a7
29 schema:citation sg:pub.10.1007/bf00662401
30 sg:pub.10.1007/bf00685924
31 sg:pub.10.1023/a:1005828731462
32 sg:pub.10.1023/a:1006391902868
33 sg:pub.10.1038/bjc.1996.357
34 https://app.dimensions.ai/details/publication/pub.1074881954
35 https://app.dimensions.ai/details/publication/pub.1077661065
36 https://app.dimensions.ai/details/publication/pub.1083239805
37 https://doi.org/10.1002/(sici)1097-0142(19980701)83:1<1::aid-cncr1>3.0.co;2-x
38 https://doi.org/10.1016/s0140-6736(95)91156-1
39 https://doi.org/10.1016/s0959-8049(01)00350-1
40 https://doi.org/10.1016/s0959-8049(02)80309-4
41 https://doi.org/10.1016/s0960-0760(01)00140-6
42 https://doi.org/10.1093/jnci/87.10.746
43 https://doi.org/10.1159/000055285
44 https://doi.org/10.1200/jco.1996.14.7.2000
45 https://doi.org/10.1200/jco.1998.16.2.453
46 https://doi.org/10.1200/jco.2000.18.22.3758
47 https://doi.org/10.1200/jco.2001.19.10.2596
48 https://doi.org/10.1200/jco.2002.10.057
49 https://doi.org/10.1200/jco.2002.10.058
50 schema:datePublished 2003-05
51 schema:datePublishedReg 2003-05-01
52 schema:description PURPOSE: This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex'). PATIENTS AND METHODS: A combined total of 423 patients received fulvestrant 250 mg as a monthly intramuscular injection. After progression on fulvestrant, some patients received another endocrine therapy. Responses to subsequent endocrine therapy were assessed using a questionnaire sent to the trial investigators. Best responses were classified as a complete or partial response (CR or PR), stable disease (SD) lasting > or = 24 weeks, or disease progression. RESULTS: Follow-up data were available for 54 patients who derived clinical benefit (CB, defined as CR, PR or SD) from fulvestrant and who received subsequent endocrine therapy, resulting in a PR in 4 patients, SD in 21 patients, and disease progression in 29 patients. Data were available for 51 patients who derived no CB from fulvestrant and who received further endocrine therapy, resulting in a PR in 1 patient, SD in 17 patients, and disease progression in 33 patients. Aromatase inhibitors were used as subsequent endocrine therapy in > 80% of patients. CONCLUSIONS: After progression on fulvestrant, patients may retain sensitivity to other endocrine agents. Fulvestrant provides an additional option to existing endocrine therapies for the treatment of advanced or metastatic breast cancer in postmenopausal women, and may provide the opportunity to extend the sequence of endocrine regimens before cytotoxic chemotherapy is required.
53 schema:genre research_article
54 schema:inLanguage en
55 schema:isAccessibleForFree false
56 schema:isPartOf N04abb0dab7e84360acdab802378e280a
57 N86de86730f1f4d3e85aed20fcb2b2951
58 sg:journal.1092777
59 schema:name Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy
60 schema:pagination 207-211
61 schema:productId N36620398a8e0414182bd5951b66947d2
62 N6273794cf9a64c06b13e71b1e3a7ee86
63 N6e1fb4dc93954e35b315fa44b5dcb817
64 N9b1cdfc6468242059bb478d29a1b9997
65 Nd142df94347b40938abc2d2210f2ec75
66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001709392
67 https://doi.org/10.1023/a:1023983032625
68 schema:sdDatePublished 2019-04-10T16:40
69 schema:sdLicense https://scigraph.springernature.com/explorer/license/
70 schema:sdPublisher N45fec165794e4a9b90feea944202e8db
71 schema:url http://link.springer.com/10.1023%2FA%3A1023983032625
72 sgo:license sg:explorer/license/
73 sgo:sdDataset articles
74 rdf:type schema:ScholarlyArticle
75 N04abb0dab7e84360acdab802378e280a schema:issueNumber 2
76 rdf:type schema:PublicationIssue
77 N06d9f9480df241ffa0c27c0a5c6b84fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Triazoles
79 rdf:type schema:DefinedTerm
80 N0d104b7458a84503afadc5f6c1559513 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Follow-Up Studies
82 rdf:type schema:DefinedTerm
83 N10ba7e6ea80f413c9547c39e21bbd0cf rdf:first sg:person.01324174537.45
84 rdf:rest N802275c9979f4510abd7a9273add7cb2
85 N1a03e5469ae3477bb6ba70b1613b309f schema:name Haematologische/Oncologische Praxis, Hamburg, Germany
86 rdf:type schema:Organization
87 N1cc4e956d9644512b426ce156a2a2432 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Retrospective Studies
89 rdf:type schema:DefinedTerm
90 N26b43798dcd24300b05e1e9d69c1e02a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Down-Regulation
92 rdf:type schema:DefinedTerm
93 N278f4e9fd1934876a1276fd4aa5e1f0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Breast Neoplasms
95 rdf:type schema:DefinedTerm
96 N2b0bef58d98c4ec1a24e114f39fac16b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Treatment Outcome
98 rdf:type schema:DefinedTerm
99 N36620398a8e0414182bd5951b66947d2 schema:name doi
100 schema:value 10.1023/a:1023983032625
101 rdf:type schema:PropertyValue
102 N453f92c28598417f98e98ba1d51931c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Postmenopause
104 rdf:type schema:DefinedTerm
105 N45fec165794e4a9b90feea944202e8db schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 N5aed25bae80f40e7a52b7ca6a589cd18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Aromatase Inhibitors
109 rdf:type schema:DefinedTerm
110 N5dc5591765ce49609288c6bd53d9f90b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Estrogen Receptor Modulators
112 rdf:type schema:DefinedTerm
113 N6273794cf9a64c06b13e71b1e3a7ee86 schema:name nlm_unique_id
114 schema:value 8111104
115 rdf:type schema:PropertyValue
116 N68bcfbdaf34e4261b72342252761c8bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Aged, 80 and over
118 rdf:type schema:DefinedTerm
119 N6de0ae024d704e4d95933e56d675c786 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Estradiol
121 rdf:type schema:DefinedTerm
122 N6e1fb4dc93954e35b315fa44b5dcb817 schema:name readcube_id
123 schema:value 082435e4f60ab6666305e03723d31a4ae196dc9d7d5ffa0d4eb63c7130cfb8c7
124 rdf:type schema:PropertyValue
125 N7b88e956da20412f879b89a4c4131bc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Drug Resistance, Neoplasm
127 rdf:type schema:DefinedTerm
128 N802275c9979f4510abd7a9273add7cb2 rdf:first sg:person.07760047337.32
129 rdf:rest N8b356e33a62f46528ed2379718f3761c
130 N85d49a0f0a16402abdf71211e6551d8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Salvage Therapy
132 rdf:type schema:DefinedTerm
133 N86de86730f1f4d3e85aed20fcb2b2951 schema:volumeNumber 79
134 rdf:type schema:PublicationVolume
135 N87d2da6e1c8b4f838f239a037041891a rdf:first sg:person.07764637207.20
136 rdf:rest N10ba7e6ea80f413c9547c39e21bbd0cf
137 N8b356e33a62f46528ed2379718f3761c rdf:first sg:person.01117361752.88
138 rdf:rest Ne74507f1dcdc4e68b61341f5a3f165de
139 N9b1cdfc6468242059bb478d29a1b9997 schema:name dimensions_id
140 schema:value pub.1001709392
141 rdf:type schema:PropertyValue
142 Na3a19d10152d4f50a43c5b09f23a8418 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Middle Aged
144 rdf:type schema:DefinedTerm
145 Nbbaf5e80fc574f789f597f3d287193bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Megestrol Acetate
147 rdf:type schema:DefinedTerm
148 Nc720a8327e7a4360836b6132fcac19b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Adult
150 rdf:type schema:DefinedTerm
151 Nc73a66ce19714d13ac0e865ff936b177 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Androstenedione
153 rdf:type schema:DefinedTerm
154 Nd142df94347b40938abc2d2210f2ec75 schema:name pubmed_id
155 schema:value 12825855
156 rdf:type schema:PropertyValue
157 Ne1fd5681b3cb416e8947f2bbaa53c0a7 rdf:first sg:person.0706143575.32
158 rdf:rest N87d2da6e1c8b4f838f239a037041891a
159 Ne74507f1dcdc4e68b61341f5a3f165de rdf:first sg:person.01271107205.26
160 rdf:rest rdf:nil
161 Ne77e59d02c7c469595230c686e06b318 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Double-Blind Method
163 rdf:type schema:DefinedTerm
164 Nea6bc5aec783481387c3832282ead3ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Aged
166 rdf:type schema:DefinedTerm
167 Nec2c1416cae44162ba593d96adbf5549 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Humans
169 rdf:type schema:DefinedTerm
170 Nec6133a8a1264cfc9747d131a4dccadf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Disease Progression
172 rdf:type schema:DefinedTerm
173 Nf5ef4d9fcac943418d18753eb7238ba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Female
175 rdf:type schema:DefinedTerm
176 Nfab6b675571a4ee9bd4b4024ea2e7933 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Enzyme Inhibitors
178 rdf:type schema:DefinedTerm
179 Nfb27ebde1c2b4886bd39d2d649c84d12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Nitriles
181 rdf:type schema:DefinedTerm
182 Nfecae56841424ed5a9b0783260caacab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Antineoplastic Agents, Hormonal
184 rdf:type schema:DefinedTerm
185 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
186 schema:name Medical and Health Sciences
187 rdf:type schema:DefinedTerm
188 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
189 schema:name Oncology and Carcinogenesis
190 rdf:type schema:DefinedTerm
191 sg:journal.1092777 schema:issn 0167-6806
192 1573-7217
193 schema:name Breast Cancer Research and Treatment
194 rdf:type schema:Periodical
195 sg:person.01117361752.88 schema:affiliation https://www.grid.ac/institutes/grid.63368.38
196 schema:familyName Osborne
197 schema:givenName C.K.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117361752.88
199 rdf:type schema:Person
200 sg:person.01271107205.26 schema:affiliation https://www.grid.ac/institutes/grid.476460.7
201 schema:familyName Mauriac
202 schema:givenName L.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271107205.26
204 rdf:type schema:Person
205 sg:person.01324174537.45 schema:affiliation N1a03e5469ae3477bb6ba70b1613b309f
206 schema:familyName Kleeberg
207 schema:givenName U.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324174537.45
209 rdf:type schema:Person
210 sg:person.0706143575.32 schema:affiliation https://www.grid.ac/institutes/grid.410569.f
211 schema:familyName Vergote
212 schema:givenName I.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706143575.32
214 rdf:type schema:Person
215 sg:person.07760047337.32 schema:affiliation https://www.grid.ac/institutes/grid.411417.6
216 schema:familyName Burton
217 schema:givenName G.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07760047337.32
219 rdf:type schema:Person
220 sg:person.07764637207.20 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
221 schema:familyName Robertson
222 schema:givenName J.F.R.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
224 rdf:type schema:Person
225 sg:pub.10.1007/bf00662401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044518496
226 https://doi.org/10.1007/bf00662401
227 rdf:type schema:CreativeWork
228 sg:pub.10.1007/bf00685924 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028594759
229 https://doi.org/10.1007/bf00685924
230 rdf:type schema:CreativeWork
231 sg:pub.10.1023/a:1005828731462 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018344209
232 https://doi.org/10.1023/a:1005828731462
233 rdf:type schema:CreativeWork
234 sg:pub.10.1023/a:1006391902868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037141890
235 https://doi.org/10.1023/a:1006391902868
236 rdf:type schema:CreativeWork
237 sg:pub.10.1038/bjc.1996.357 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012787769
238 https://doi.org/10.1038/bjc.1996.357
239 rdf:type schema:CreativeWork
240 https://app.dimensions.ai/details/publication/pub.1074881954 schema:CreativeWork
241 https://app.dimensions.ai/details/publication/pub.1077661065 schema:CreativeWork
242 https://app.dimensions.ai/details/publication/pub.1083239805 schema:CreativeWork
243 https://doi.org/10.1002/(sici)1097-0142(19980701)83:1<1::aid-cncr1>3.0.co;2-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1011845112
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1016/s0140-6736(95)91156-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047740754
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/s0959-8049(01)00350-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005235495
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1016/s0959-8049(02)80309-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054666367
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/s0960-0760(01)00140-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016224520
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1093/jnci/87.10.746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059819285
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1159/000055285 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021121785
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1200/jco.1996.14.7.2000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082907367
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1200/jco.1998.16.2.453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083213024
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1200/jco.2000.18.22.3758 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074728220
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1200/jco.2001.19.10.2596 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074814003
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2002.10.057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203147
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1200/jco.2002.10.058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203148
268 rdf:type schema:CreativeWork
269 https://www.grid.ac/institutes/grid.410569.f schema:alternateName Universitaire Ziekenhuizen Leuven
270 schema:name University Hospitals, Leuven, Belgium
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.411417.6 schema:alternateName Louisiana State University Health Sciences Center Shreveport
273 schema:name Louisiana State University Health Science Center, Shreveport, LA, USA
274 rdf:type schema:Organization
275 https://www.grid.ac/institutes/grid.412920.c schema:alternateName Nottingham City Hospital
276 schema:name Nottingham City Hospital, Nottingham, UK
277 rdf:type schema:Organization
278 https://www.grid.ac/institutes/grid.476460.7 schema:alternateName Institut Bergonié
279 schema:name Bergonie Institute, Bordeaux, France
280 rdf:type schema:Organization
281 https://www.grid.ac/institutes/grid.63368.38 schema:alternateName Houston Methodist
282 schema:name Breast Center at Baylor College of Medicine and Methodist Hospital, Houston, TX, USA
283 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...